Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Carboprost is a synthetic prostaglandin similar to prostaglandin F2 alpha (dinoprostone). It induces the contractility of the uterine smooth muscles. It is administered intramuscularly in postpartum hemorrhages due to uterine atony when other drugs have not been effective.
Since the last update we have not found published data on its excretion in breastmilk.
Its very rapid elimination and its very low concentration in plasma (high intramuscular doses only produce concentrations of picograms in plasma: Pfizer 2014) make it very unlikely that significant quantities will transfer into breastmilk.
It has been widely used in obstetrics without encountering problems in breastfeeding babies.
Several experts consider its use during breastfeeding to be probably compatible. (Hale 2019, Briggs 2017).